GSA CAPITAL PARTNERS LLP - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 169 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2022. The put-call ratio across all filers is 0.65 and the average weighting 0.3%.

Quarter-by-quarter ownership
GSA CAPITAL PARTNERS LLP ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$1,231
+136.7%
44,716
+192.0%
0.10%
+101.9%
Q2 2023$520
-42.0%
15,312
-38.6%
0.05%
-41.6%
Q1 2023$897
-99.7%
24,942
+124.4%
0.09%
+117.1%
Q3 2022$312,000
-56.9%
11,116
-40.6%
0.04%
-54.9%
Q4 2021$724,000
+121.4%
18,726
+91.7%
0.09%
+145.9%
Q2 2021$327,0009,7690.04%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q1 2022
NameSharesValueWeighting ↓
Kynam Capital Management, LP 3,200,000$88,064,00014.40%
Octagon Capital Advisors LP 759,898$20,912,3933.21%
TSP Capital Management Group, LLC 251,695$6,926,6452.67%
5AM Venture Management, LLC 310,270$8,538,6302.46%
COMMODORE CAPITAL LP 706,665$19,447,4212.27%
ACUTA CAPITAL PARTNERS, LLC 122,341$3,366,8242.26%
Redmile Group, LLC 1,635,938$45,021,0142.14%
RTW INVESTMENTS, LP 3,463,201$95,307,2922.01%
Eversept Partners, LP 588,143$16,185,6951.37%
Affinity Asset Advisors, LLC 150,000$4,128,0001.16%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders